Fibrinogen. An old hemostatic protein with a new function: Non-invasive marker of subclinical atherosclerosis;Fibrinógeno. Vieja proteína hemostática con nueva función: Marcador no invasivo de aterosclerosis subclínica

Medicina Clinica

Volumn 124, Issue 20, 2005, Pages 790-794

  Páramo, José A ^a,b,c   Rodríguez, José A ^a   Orbe, Josune ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular diseases; Fibrinogen; Inflammation

Indexed keywords

ACUTE PHASE PROTEIN; ANCROD; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BATROXOBIN; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SNAKE VENOM; THIENO[3,2 C]PYRIDINE DERIVATIVE; THROMBIN; TICLOPIDINE;

APHERESIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE MARKER; DRUG EFFECT; ENVIRONMENTAL FACTOR; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEREDITY; HUMAN; INFLAMMATION; PREDICTION; PROTEIN FUNCTION; REVIEW; SUBCLINICAL ATHEROSCLEROSIS; SYMPTOMATOLOGY; THROMBOSIS;

EID: 21244437238     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075852     Document Type: Review

References (71)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;430:868-74.
2. Páramo JA, Orbe J, Rodríguez JA. Estabilización de la placa de ateroma: un nuevo concepto basado en la biología dinámica de la aterosclerosis. Med Clin (Barc). 2003;121:583-7.
3. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of nontraditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686-95.
4. Mosseson MW, Siebelist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci. 2001;936:312-27.
5. Castell JV, Gómez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1197-86.
6. Perz RL, Ritzenthaler JD, Roman J. Transcriptional regulation of the interleukin-1 beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol. 1999;20:1059-66.
7. Collet JP, Lesty C, Montalescot G, Weisel JW. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem. 2003;278:21331-5.
8. Scott EM, Ariens AS, Grant P. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1558-66.
9. Margaglione M, Cappucci G, Colaizzo D, Pirro C, Vecchione G, Grandone E, et al. Fibrinogen plasma levels in an apparently healthy general population. Relation to environmental and genetic determinants. Thromb Haemost. 1998;80:805-10.
10. Humphries SE, Luong LA, Montgomery HE, Day INM, Mohamed-Ali V, Yudkin JS. Gene environment interaction in the determination of levels of plasma fibrinogen. Thromb Haemost. 1999;82:818-25.
11. De Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357:101-5.
12. Dunn EJ, Ariens RA, De Lange M, Snieder H, Turney JH, Spector TD, et al. Genetics of fibrin clot structure: a twin study. Blood. 2004;103:1735-40.
13. Souto JC, Almasy L, Borrell M, Gari M, Martínez E, Mateo J, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation. 2000;101:1546-51.
14. Freeman MS, Mansfield MW, Barret JH, Grant PJ. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol. 2002;22:506-10.
15. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis (I). New genes and pathways. Circulation. 2004;110:1868-3.
16. Iacovello I, Vischetti M, Zito F, Donati MB. Genes encoding fibrinogen and cardiovascular risk. Hypertension. 2001;38:1199-203.
17. Falls LA, Farrell DH. Resistance of gammaA/gamma' fibrin clots to fibrinolysis. J Biol Chem. 1997;272:14251-6.
18. Grieninger G. Contribution of the alpha EC domain to the structure and function of fibrinogen-420. Ann NY Acad Sci. 2001;936:44-64.
19. Carter AM, Mansfield MW, Stickland MH, Grant PJ. Beta-fibrinogen gene -455G/A polymorphism and fibrinogen levels. Risk factor for coronary artery disease in subjects with NIDDM. Diabetes Care. 1996;19:1265-8.
20. Behague I, Poirier O, Nicaud V, Evans A, Arveile D, Luc G, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation. 1996;93:440-9.
21. Zito F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, Iacovello L. ACLI polymorphism in the fibrinogen beta-chain is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a simple of GISSI-2 patients. Arterioscler Thromb Vasc Biol. 1997;17:3489-94.
22. De Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Cansen H, Groenemeier B, et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary aterosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen REGRESS group. Arterioscler Thromb Vasc Biol. 1998;18:265-71.
23. Folsom AR, Aleksic N, Ahn C, Boerwinkle E, Wu KK. Beta fibrinogen gene -455G/A polymorphism and coronary heart disease incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2001;11:166-70.
24. Martiskainen M, Pohjasvaara T, Mikkelson J, Mantyla R, Kunnas T, Laippala P, et al. Fibrinogen gene promoter -455 allele as risk factor for lacunar stroke. Stroke. 2003;34:886-91.
25. Martínez-Vila E, Páramo JA, Beloqui O, Irimia P, Colina I, Monreal I, et al. Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects. Cerebrovasc Dis. 2003;13:356-62.
26. Standeven KF, GRant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA. Functional analysis of the fibrinogen A alpha Thr312 ALA polymorphism: effects on fibrin structure and function. Circulation. 2003;107:2326-30.
27. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517-32.
28. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-63.
29. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet. 1987;2:986-8.
30. Oosthuizen W, Vorster HH, Jerling JC, Barnard HC, Smuts CM, Silvis N, et al. Both fish oil and olive oil lowered plasma fibrinogen in women with high baseline fibrinogen levels. Thromb Haemost. 1994;72:557-62.
31. Rokita H, Neta R, Sipe JD. Increased fibrinogen synthesis in mice during the acute phase response: co-operative interaction of interleukin 1, interleukin 6, and interleukin-1 receptor antagonists. Cytokine. 1993;5:454-8.
32. Phear D, Stirland R. The value of estimating fibrinogen and C-reactive protein levels in myocardial ischemia. Lancet. 1957;2:270-5.
33. Meade TW, Brozovic M, Haines AP, Imenson JD, Mellows S, Miller GJ, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-8.
34. Kannel WB, Wolf PA, Castelli WP, D'Agostino RBD. Fibrinogen and risk of cardiovascular disease: The Framingham study. J Am Med Assoc. 1987;258:1183-6.
35. Fowkes FG, Connor JM, Smith FB, Word J, Donan PT, Lowe GDO. Fibrinogen genotype and risk of peripheral aterosclerosis. Lancet. 1992;339:693-6.
36. Heinrich J, Balleisen L, Schulte H, Assman G, Van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-9.
37. Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerotic Risk in Communities (ARIC) Study. Circulation. 1997;96:1102-8.
38. Sweetnam PM, Yarnell JW, Lowe GD, Baker IA, O'Brien JR, Rumley A, et al. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol. 1998;100:582-8.
39. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: the Scottish Heart Health Study. Eur Heart J. 1998;19:55-62.
40. Tracy RP, Arnold AM, Ettinger W, Fried C, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:1776-83.
41. Reganon E, Vila V, Ferrando F, Martinez-Sales V, Fayos L, Ruano M, et al. Elevated high molecular weight fibrinogen in plasma is predictive of coronary ischemic events alter acute myocadial infarction. Thromb Haemost. 1999;82:1403-5.
42. Lindahl B, Toss H, Siegbhan A, Venge P, Wallentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation-to long-term mortality in instable coronary artery disease. N Engl J Med. 2000;343:1139-47.
43. Stec JJ, Silbershatz H, Tofler G, Matheney TH, Sutherland P, Lipinska I, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation. 2000;102:1634-8.
44. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analysis of prospective studies. J Am Med Assoc. 1998;279:1477-82.
45. Maresca G, Di Blasco A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999;19:1368-77.
46. Sánchez PL, Morinigio JL, Pabon P, Martin F, Palacios IF, Luengo C. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndromes. Heart. 2004;90:264-9.
47. Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2003;26:381-6.
48. Mancini J, Dahlof B, Diez J. Surrogate markers for cardiovascular disease. Structural markers. Circulation. 2004;109 Suppl 4:22-30.
49. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease. Functional markers. Circulation. 2004;109 Suppl 4:31-46.
50. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
51. Páramo JA, Orbe J, Beloqui O, Benito A, Colina I, Martínez-Vila E, et al. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke. 2004;35:1085-9.
52. Páramo JA, Beloqui O, Roncal C, Benito A, Orbe J. Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica. 2004;89:1226-31.
53. Palmieri V, Celentano A, Roman MJ, de Simeone G, Lewis M, Best L, et al, for the Strong Heart Study Investigators. Fibrinogen and preclinical echocardiographic target organ damage. Hypertension. 2001;38:1068-74.
54. Mauriello A, Sangiorgi G, Palmieri G, Virmani R, Holmes Jr DR, Schwartz RS, et al. Hyperfibrinogenemia is associated with specific hystocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks. Circulation. 2000;101:744-50.
55. Bielak LF, Klee KG, Shedy II PF, Turner ST, Schwartz RS, Peyser PA. Association of fibrinogen with quantity of coronary artery calcification measured by electron beam computed tomography. Arterioscler Thromb Vasc Biol. 2000;20:2167-71.
56. Reinhart WH. Fibrinogen: marker or mediator of vascular disease? Vasc Med. 2003;8:211-6.
57. Fay WP. Hyperfibrinogenemia and vascular disease: does it matter? Blood. 2004;103:1569-70.
58. Gulledge AA, Reaee F, Verheijen JH, Lord ST. A novel transgenic mouse model of hiperfibrinogenemia. Thromb Haemost. 2001;86:511-6.
59. Gulledge AA, McShea C, Schwartz T, Koch G, Lord ST. Effects of hyperfibrinogenemia on vasculature of C57BL/6 mice with and without atherogenic diet. Arterioscler Thromb Vasc Biol. 2003;23:130-5.
60. Kerlin B, Cooley BC, Iserman BH, Hernández I, Sood R, Zogg M, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood. 2004;103:1728-34.
61. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA. 1998;95:12591-5.
62. 2/Mac-1 is critical to host inflammatory response in vivo. J Clin Invest. 2004;113:1596-1606.
63. Gray AJ, Bishop JE, Reeves JT, Mecham RP, Laurent GJ. Partially degraded fibrin(ogen) stimulates fibroblast proliferation in vitro. Am J Respir Cell Mol Biol. 1995;12:684-90.
64. Busso N, Pedal V, Van Ness K, Kolodziesczy KE, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest. 1998;102:41-50.
65. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol. 1996;16:361-56.
66. De Maat M. Effect of diet, drugs, and genes on plasma fibrinogen levels. Ann NY Acad Sci. 2001;936:509-21.
67. Tekin A, Tekin G, Guzelsoy D, KayaGurel CV, Yigit Z, Ulutin T. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically coronary artery disease. Am J Cardiol. 2004;94:206-9.
68. Leibovitz Hazanov N, Frieman A, Elly I, Gavish D. Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the antiinflammatory effects of statins. Isr Med Assoc J. 2004;8:456-9.
69. Sherman DG. Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step? Cerebrovasc Dis. 2004;17 Suppl 1:138-43.
70. Andronati SA, Karaseva TL, Krysko AA. Peptidomimetics-antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr Med Chem. 2004;11:1183-211.
71. Jaeger BR. The HELP system for the treatment of atherothrombotic disorders: a review. Ther Apher Dial. 2003;7:391-6.